+

WO2009030087A1 - Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine - Google Patents

Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine Download PDF

Info

Publication number
WO2009030087A1
WO2009030087A1 PCT/CN2007/070627 CN2007070627W WO2009030087A1 WO 2009030087 A1 WO2009030087 A1 WO 2009030087A1 CN 2007070627 W CN2007070627 W CN 2007070627W WO 2009030087 A1 WO2009030087 A1 WO 2009030087A1
Authority
WO
WIPO (PCT)
Prior art keywords
pebp4
polypeptide
cells
apoptosis
protein
Prior art date
Application number
PCT/CN2007/070627
Other languages
English (en)
Chinese (zh)
Inventor
Xiaojian Wang
Nan Li
Xuetao Cao
Original Assignee
Zhejiang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University filed Critical Zhejiang University
Priority to PCT/CN2007/070627 priority Critical patent/WO2009030087A1/fr
Publication of WO2009030087A1 publication Critical patent/WO2009030087A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Definitions

  • the present invention is in the field of biotechnology and medicine, and in particular, the present invention relates to the use of phosphat idylethanolamine b inding prote in 4 (PEBP4) or its coding sequence [
  • PEBP family proteins are a class of soluble cytosolic proteins that specifically bind to phospholipids such as phosphatidylethanolamine (PE), and all members of this family contain conserved regions that bind to PE.
  • the PEBP family has a wide range of sources and is highly conservative in evolution. From flowering plants such as tirrhinum and A bidopsis thai i ana, parasites such as Plasmodium falciparium, nematode worms such as Onchocerca volvulus and Toxocara can is Yeast such as Saccharomyces cere visiae, insects such as insects (/3 ⁇ 4 5 ⁇ (3 ⁇ 4 ⁇ ?
  • PEBP protein has a wide range of distribution, but is highly expressed mainly in the highly growing regions of the cells (testis, developing brain, inflorescence dividing tissues of flowering plants). Only mPEBP2 and mPEBP3 are only expressed in adult testicular tissue.
  • PEBP family proteins are diverse.
  • the PEBP protein in flowering plants is mainly involved in morphogenesis and individual occurrence (flowering signal and dividing tissue growth).
  • three plant proteins such as CEN, TFL1 and SP are related to flowering of snapdragon, rat ear grass and tomato, CEN and TFL-1. Mutations can induce normal, undefined flowering to determine flowering, while SP in tomato is involved in regulating the regeneration cycle of plant dividing tissues.
  • Drosophila 0PB is capable of binding odor molecules and is an effector molecule that binds to odorants; Agl6 of P. sinensis is a major antigen in the serum of patients infected with P.
  • Plasmodium PfPEBP may be part of the cell surface secreted protein, involved in protecting worms from host immune responses; yeast TFS 1 is able to inhibit CDC25 mutants; bovine brain PEBP binds to multiple nucleotides involved in signal transduction pathways, The presence of small G proteins, combined with GTP and GDP.
  • PEBP 1 in human and rat, mouse is a precursor protein of hippocampal cholinergic neurostimulating peptide (HCNP). This peptide can stimulate acetylcholine synthesis and cholinergic activity in rat neurons after release from the apical end of PEBP 1. .
  • HCNP hippocampal cholinergic neurostimulating peptide
  • PEBP1 also known as the raf kinase inhibitor protein RKIP
  • RKIP mitogen-activated protein
  • mPEBP2 can bind to B-Raf and MEK, and the expression pattern is similar. It is reported that spermatogenesis and post-testicular sperm maturation can occur during MAPK pathway activation. mPEBP2 may therefore regulate MAPK pathway by specific regulation. The fine process plays a regulatory role.
  • PEBP has recently been found to be a new class of serine protease inhibitors that inhibit serine protease activity in neural tissues.
  • PEBP family proteins Due to its specific binding to phospholipids (especially PE), binding to G protein, and its distribution in highly cell-grown regions, PEBP family proteins are likely involved in membrane structure modification during cell growth, in membrane biosynthesis, Membrane fluidity and functional domain play an important role in the formation of membrane-separating antigens; or as messenger molecules between cell membranes and cytoplasm involved in signal transduction.
  • a human phosphatidylethanolamine binding polypeptide PEBP4, or a coding sequence thereof, for use in the preparation of a composition for inhibiting apoptosis.
  • the PEBP4 polypeptide is selected from the group consisting of
  • ( C ) a fusion protein of a PEBP4 polypeptide, which has a function of inhibiting apoptosis.
  • the coding sequence is selected from the group consisting of:
  • the composition is a pharmaceutical composition.
  • the composition is for use in treating or ameliorating a disease or condition associated with apoptosis.
  • the disease or condition includes: stroke, myocardial infarction, Alzheimer's disease, Parkinson's disease, AIDS, retinal degenerative disease, hematopoietic system disease, anti-drug, or aging.
  • the composition comprises a pharmaceutically acceptable carrier, diluent or excipient, and from 0.001 to 99.99% by weight of a human PEBP4 polypeptide or a coding sequence thereof, to the composition
  • the total weight is based on the basis.
  • the cell is selected from the group consisting of MCF-7 cells and L929 cells.
  • the apoptosis is caused by an inducer of apoptosis.
  • the inducer of apoptosis is TNF ⁇ .
  • kits or reagents for detecting breast cancer In another embodiment of the invention, it is also used to prepare a kit or reagent for detecting breast cancer.
  • a human phosphatidylethanolamine binding polypeptide ie, ⁇ 4
  • a method of an agonist or inhibitor comprising:
  • control group is a cell culture system expressing a PEBP4 polypeptide or a cell culture system supplemented with a PEBP4 polypeptide
  • test group is a PEBP4 polypeptide to which a test substance is added.
  • cell culture system or a cell culture system to which a test substance and a PEBP4 polypeptide are added;
  • the apoptosis rate of the cells in the test group is increased compared with the control group, indicating that the test substance is an inhibitor of the potential PEBP4 polypeptide;
  • the apoptosis rate of the cells in the test group was decreased as compared with the control group, indicating that the test substance was an agonist of the latent PEBP4 polypeptide.
  • the inducer of apoptosis is TNF a .
  • the cell culture system is a culture system of MCF-7 cells or L929 cells.
  • the apoptosis rate of the cells in the test group and the apoptosis of the positive control group are further included. The ratio was compared, and the positive control group was a cell culture system to which an anti-PEBP4 antibody, an antisense nucleotide, or an interfering RNA was added.
  • the inhibitor of PEBP4 screened according to the method of the present invention is used for the preparation of a medicament for treating cancer, preferably breast cancer.
  • a human phosphatidylethanolamine binding polypeptide or a coding sequence thereof for the preparation of a kit or reagent for detecting breast cancer.
  • the reagent is an antibody, a primer, or a probe.
  • the present invention also provides the use of an antibody against human phosphatidylethanolamine-binding polypeptide, PEBP4, for the preparation of a breast cancer diagnostic kit.
  • PEBP4 human phosphatidylethanolamine-binding polypeptide
  • the invention also provides a kit for diagnosing breast cancer, the kit comprising:
  • the invention also provides the use of a human phosphatidylethanolamine binding polypeptide, PEBP4, or a coding sequence thereof, for use as a marker for breast cancer.
  • PEBP4 polypeptide is highly expressed in breast cancer tissue but not in normal breast tissue.
  • the invention also provides the use of a human phosphatidylethanolamine binding polypeptide, an inhibitor of PEBP4, for use in the preparation of a pharmaceutical composition for the treatment of breast cancer.
  • the inhibitor of PEBP4 is selected from the group consisting of: an anti-PEBP4 antibody, an antisense nucleotide, or an interfering RNA.
  • Figure 1 shows the analysis of specific binding of purified anti-PEBP4 protein antibody to PEBP4.
  • FIG 2 shows the tissue distribution of the human PEBP4 protein immunohistochemistry shown in the present invention. The results suggest that PEBP4 protein is selectively highly expressed in breast cancer tissues.
  • Figures 2a and 2b show human breast cancer tissues;
  • Figures 2c and 2d show normal human breast tissue.
  • Figure 3 shows the Western blot analysis of the expression of PEBP4 protein in L929 cells transfected with eukaryotic recombinant expression vector of human PEBP4.
  • FIG. 4 shows the analysis of RNA interference in human PEBP4 protein expression in MCF-7 breast cancer cells.
  • 4A is a Western blot analysis; and
  • FIG. 4B is an RT-PCR analysis.
  • Figure 5 shows the effect of human PEBP4 protein overexpression on TNF a-induced apoptosis in L929 cells. The results suggest that overexpression of PEBP4 protein inhibits TNF a-induced apoptosis in L929 cells.
  • Figure 6 shows the effect of down-regulation of human PEBP4 protein on TNF-induced apoptosis in MCF-7 breast cancer cells.
  • the results suggest that down-regulation of PEBP4 protein can promote TNF a-induced MCF-7 cell apoptosis, making MCF-7 cells more sensitive to TNF a-induced apoptosis.
  • the present inventors conducted extensive and in-depth research on the effect of human phosphatidylethanolamine-binding protein 4 SP PEBP4 protein obtained from a gene library of a human dendritic cell cDNA library on apoptosis, and confirmed from various aspects through various experiments.
  • the PEBP4 polypeptide has a function of inhibiting apoptosis and can be used for preparing a composition for inhibiting apoptosis, thereby completing the present invention.
  • the association between PEBP family proteins and apoptosis and its role in apoptosis have not been reported so far.
  • the present inventors have unexpectedly found that the polypeptide has an inhibitory effect on apoptosis by studying the effect of PEBP4 on apoptosis.
  • a new use of the PEBP4 polypeptide or its coding sequence i.e., a composition for inhibiting apoptosis, has been discovered.
  • the present invention is not limited by any theory, it is presumed that the PE and phosphatidylserine present in the inner side of the membrane are eversion due to the disappearance of membrane phospholipid asymmetry due to the early stage of apoptosis: Sexual binding to PE may prevent PE valgus, inhibit the loss of membrane phospholipid asymmetry, and thus inhibit membrane morphology changes such as cell membrane disruption and disintegration caused by apoptosis, which may delay the progression of apoptosis.
  • PEBP4 protein is selectively highly expressed in breast cancer tissues. It is not expressed in normal breast tissue, suggesting that PEBP4 can be used as a tumor marker for breast cancer.
  • the inventors also found through experiments that L929 cells overexpressing PEBP4 protein significantly resisted TNF ⁇ -induced apoptosis.
  • L929 cells overexpressing PEBP4 protein significantly resisted TNF ⁇ -induced apoptosis.
  • MCF-7 breast cancer cells with high expression of human ⁇ 4 protein downregulation of ⁇ 4 expression promoted TNF ⁇ -induced apoptosis.
  • the high expression of ⁇ 4 in breast cancer tissues and the down-regulation of ⁇ 4 expression enhanced the sensitivity of breast cancer cells to TNF-induced apoptosis, suggesting that PEBP4 is likely to be a target for the treatment of breast cancer.
  • the PEBP4 polypeptide or its coding sequence can be used as a tumor marker or drug target for breast cancer to diagnose and treat breast cancer by means of immunology, biochemistry or molecular biology.
  • the invention also provides the use of a PEBP4 protein or a coding sequence thereof for the diagnosis and treatment of breast cancer.
  • human PEBP4 protein or its related inhibitors and agonists can provide new immunodiagnostic and targeted therapeutic approaches for the treatment of diseases such as tumors, inflammation, nervous system and cardiovascular diseases, and thus have great application prospects.
  • the PEBP4 protein of the present invention is selectively highly expressed in breast cancer tissues. From the above results, it can be speculated that PEBP4 may play an important role in the development of the brain, which may regulate a variety of physiological and pathological activities, and may play an important role in anti-infective, anti-inflammatory, anti-tumor, nerve growth repair, immune function regulation, etc.
  • the field of immunodiagnosis and immunotherapy has important development and application value. Studies have shown that PEBP family proteins are associated with a variety of life activities. Therefore, it is important to study and develop a new human phosphatidylethanolamine binding protein PEBP4 for diagnostic and therapeutic purposes.
  • PEBP4 protein protein
  • PEBP4 polypeptide or “human phosphatidylethanolamine binding protein 4"
  • SEQ ID NO: 2 amino acid sequence
  • the "PEBP4 polypeptide” is selected from the group consisting of:
  • polypeptide derived from (a) which is formed by substitution, deletion or addition of the amino acid sequence of SEQ ID NO: 2 with one or more amino acid residues and which has an apoptosis inhibiting function.
  • PEBP4 protein encompasses a variant form of the sequence of SEQ ID NO: 2 which has the same function as the human PEBP4 protein.
  • These variants include, but are not limited to, a number (usually 1-50, preferably 1-30, more preferably 1-20, optimally 1-10) amino acid deletions, insertions And/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and/or N-terminus.
  • a number usually 1-50, preferably 1-30, more preferably 1-20, optimally 1-10) amino acid deletions, insertions And/or substitution, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and/or N-terminus.
  • amino acids of similar or similar properties usually Does not change the function of the protein.
  • the addition of one or more amino acids at the C-terminus and/or N-terminus will generally not alter the function of the protein.
  • the term also encompasses active fragment
  • Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that hybridize to human PEBP4 DNA under high or low stringency conditions And a polypeptide or protein obtained using an antiserum against an anti-human PEBP4 polypeptide.
  • the invention also provides other polypeptides, such as fusion proteins comprising a human PEBP4 polypeptide or a fragment thereof. In addition to the nearly full length polypeptide, the present invention also encompasses soluble fragments of the human PEBP4 polypeptide.
  • the fragment has at least about 10 contiguous amino acids of the human PEBP4 polypeptide sequence, typically at least about 30 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, optimally at least about 100 consecutive amino acids.
  • fragment refers to a polypeptide that substantially retains the same biological function or activity of the native human PEBP4 protein of the invention.
  • the polypeptide fragment, derivative or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide and another compound (such as a compound that extends the half-life of the polypeptide, for example a polypeptide formed by fusion of a polyethylene glycol) or (iv) an additional amino acid sequence fused to the polypeptide sequence (eg, a leader or secretion sequence or a sequence or proprotein sequence used to purify the polypeptide, or A fusion protein for the formation of an antigenic Ig
  • isolated means that the substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment).
  • the polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotide or polypeptide is separated and purified, such as from other substances existing in the natural state. of.
  • isolated PEBP4 protein or polypeptide means that the PEBP4 polypeptide is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. Those skilled in the art will be able to purify the PEBP4 protein using standard protein purification techniques. A substantially pure polypeptide produces a single major band on a non-reducing polyacrylamide gel.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, preferably a recombinant polypeptide.
  • the polypeptide of the present invention may be a naturally purified product, either a chemically synthesized product, or produced by recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plant, insect, and mammalian cells).
  • the polypeptide of the invention may be glycosylated, or may be non-glycosylated, depending on the host used in the recombinant production protocol. Polypeptides of the invention may also or may not include an initial methionine residue.
  • polypeptides of the invention can also be used in conjunction with proteins of molecular weights such as BSA to form polypeptide conjugates.
  • the conjugate consists of a polypeptide, a crosslinker, and BSA, wherein the crosslinker is preferably glutaraldehyde, EDAC.
  • Polynucleotide encoding a PEBP4 protein or polypeptide may be in the form of DNA or RNA.
  • DNA forms include cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • the DNA can be a coding strand or a non-coding strand.
  • the coding region sequence encoding the mature polypeptide may be identical to the coding region sequence shown in SEQ ID NO: 1, or may be a degenerate variant.
  • a "degenerate variant" in the present invention refers to a nucleic acid sequence which encodes a protein having SEQ ID NO: 2 but differs from the coding region sequence set forth in SEQ ID NO: 1.
  • polynucleotide encoding a PEBP4 protein or polypeptide and “PEBP4 polypeptide coding sequence” are used interchangeably and may include a polynucleotide encoding PEBP4 or a polynucleoside further comprising additional coding and/or non-coding sequences. acid.
  • the polynucleotide is isolated from a human dendritic cell cDNA library, the sequence of which is set forth in SEQ ID NO: 1, which comprises a polynucleotide sequence of 874 bases in length.
  • the open reading frame is located at positions 65-749 and encodes a human PEBP4 protein (SEQ ID NO: 2) of 227 amino acids in length.
  • the present invention also relates to variants of the above polynucleotides which encode fragments, analogs and derivatives of polypeptides or polypeptides having the same amino acid sequence as the present invention.
  • Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide which may be a substitution, deletion or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide encoded thereby. .
  • the polypeptides and polynucleotides of the invention are preferably provided in isolated form, more preferably purified to homogeneity.
  • the human PEBP4 full-length sequence of the present invention or a fragment thereof can be usually obtained by a PCR amplification method, a recombinant method or a synthetic method.
  • primers can be designed in accordance with the disclosed nucleotide sequences, particularly open reading frame sequences, and can be prepared using commercially available cDNA libraries or conventional methods known to those skilled in the art.
  • the library is used as a template to amplify the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then the amplified fragments are spliced together in the correct order.
  • the recombination method can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it to a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.
  • synthetic sequences can be used to synthesize related sequences, especially when the fragment length is short. Usually, a long sequence of fragments can be obtained by first synthesizing a plurality of small fragments and then connecting them.
  • DNA sequence encoding the protein of the present invention (or a fragment thereof, or a derivative thereof) completely by chemical synthesis.
  • the DNA sequence can then be introduced into various existing DNA molecules (e.g., vectors) and cells known in the art.
  • mutations can also be introduced into the protein sequences of the invention by chemical synthesis.
  • the invention also relates to vectors comprising the polynucleotides of the invention, and host cells genetically engineered using the vector of the invention or the PEBP4 protein coding sequence, and methods of producing the polypeptides of the invention by recombinant techniques.
  • polynucleotide sequences of the present invention can be used to express or produce recombinant PEBP4 polypeptides by conventional recombinant DNA techniques. Generally there are the following steps:
  • the invention also relates to agonists or inhibitors of PEBP4 polypeptides.
  • an inhibitor of a PEBP4 polypeptide refers to a substance that is capable of combating, inhibiting or reducing the activity or expression of a PEBP4 polypeptide.
  • Common inhibitors include antibodies, antisense nucleotides, interfering RNA (RNAi), certain natural extracts or compounds.
  • an agonist of a PEBP4 polypeptide refers to a substance that is capable of increasing, or promoting, the activity or expression of a PEBP4 polypeptide.
  • Common promoters include PEBP4 fusion proteins, certain natural extracts or compounds, and the like.
  • an agonist or inhibitor of the PEBP4 polypeptide can be screened by an in vitro screening method.
  • the method includes:
  • control group is a cell culture system expressing a PEBP4 polypeptide or a cell culture system supplemented with a PEBP4 polypeptide
  • test group is a PEBP4 polypeptide to which a test substance is added.
  • cell culture system or a cell culture system to which a test substance and a PEBP4 polypeptide are added;
  • the apoptosis rate of the cells in the test group is increased compared with the control group, indicating that the test substance is an inhibitor of a potential PEBP4 polypeptide; wherein, in the test group, the apoptosis of the cells is compared with the control group. A decrease in the rate indicates that the test substance is an agonist of the potential PEBP4 polypeptide.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a safe therapeutically effective amount (eg, 0.001 to 99% by weight) of a PEBP4 polypeptide of the invention or a polynucleotide encoding the same (or an agonist, or inhibitor thereof) And a pharmaceutically acceptable carrier or excipient.
  • the human PEBP4 polypeptide is present in an amount of from 0.001 to 99.9% by weight, preferably from 0.01 to 95% by weight, more preferably from 0.1 to 90% by weight, most preferably from 0.5 to 80% by weight.
  • an effective amount refers to an amount of a therapeutic agent that treats, alleviates or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or prophylactic effect.
  • the precise effective amount for a subject will depend on the size and health of the subject, the nature and extent of the condition, and the combination of therapeutic and/or therapeutic agents selected for administration. Therefore, it is useless to specify an accurate effective amount in advance. However, for a given condition, routine experimentation can be used to determine the effective amount that the clinician can judge.
  • an effective dose is about 0.01 mg/kg to 50 mg/kg, respectively.
  • the polypeptide of the invention, its agonist, or an inhibitor thereof is from 0.05 mg/kg to 10 mg/kg body weight.
  • the active substances of the invention may also be used together with other therapeutic agents.
  • pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent.
  • the term refers to pharmaceutical carriers which do not themselves induce the production of antibodies harmful to the individual receiving the composition and which are not excessively toxic after administration.
  • These vectors are well known to those of ordinary skill in the art.
  • Such carriers include, but are not limited to, saline, buffer, dextrose, water, glycerol, ethanol, adjuvants, or combinations thereof.
  • the pharmaceutically acceptable carrier in the compositions of the present invention may contain liquids such as water, saline, glycerol and ethanol.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like may also be present in these carriers.
  • composition of the present invention may contain, in addition to the PEBP4 polypeptide or the coding sequence or its agonist as an active ingredient, an additional active substance for inhibiting apoptosis for treating or alleviating the disease or sign associated with apoptosis.
  • Shapes including but not limited to: stroke, myocardial infarction, Alzheimer's disease, Parkinson's disease, AIDS, retinal degenerative disease, hematopoietic disease, anti-drug, or aging.
  • the additional active substance is selected from the group consisting of: rasagiline, neurotrophic factor, midodyl, cyclosporine VIII, N-acetylcysteine, glutathione, nerve cell growth factor, Sphingosine 1 -phosphate or a combination thereof.
  • the invention also provides compositions comprising a PEBP4 polypeptide or an inhibitor of a coding sequence.
  • the composition can be used to treat and alleviate diseases associated with apoptosis, such as cancer (preferably breast cancer).
  • the composition may also contain additional active substances that promote apoptosis, including but not limited to: epi-ethylidene, 5-fluorouracil, cisplatin, vincristine, or combinations thereof.
  • additional active substances that promote apoptosis including but not limited to: epi-ethylidene, 5-fluorouracil, cisplatin, vincristine, or combinations thereof.
  • the pharmaceutical preparation should be matched to the mode of administration.
  • the pharmaceutical composition of the present invention can be prepared into an injection form, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods.
  • Pharmaceutical compositions such as injections, solutions, tablets and capsules are preferably manufactured under sterile conditions.
  • the amount of active ingredient administered is a therapeutically effective amount, for example from about 1 microgram per kilogram body weight to about 5 milligrams per kilogram body weight per day.
  • the pharmaceutical composition of the present invention can be administered orally, subcutaneously, intradermally, intravenously or the like.
  • the therapeutic dosage regimen can be a single dose regimen or a multiple dose regimen.
  • a pharmaceutical composition When a pharmaceutical composition is used, a safe and effective amount of a PEBP4 polypeptide, an agonist thereof, or an inhibitor thereof, is administered to a mammal, especially a human. Specific doses should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician. Further, the PEBP4 polypeptide of the present invention, an agonist thereof, or an inhibitor thereof may be used alone for inhibiting apoptosis, and may be used in combination with other substances. Advantages of the invention
  • PEBP4 polypeptide or its encoding polynucleotide as a pharmaceutical composition may be used alone or in combination with other polypeptides, polynucleotides, or in combination with other drugs and therapeutic means for the treatment of apoptosis-related diseases;
  • PEBP4 polypeptide is highly expressed in breast cancer cells and can be used as a marker or therapeutic target for breast cancer for the diagnosis and treatment of breast cancer.
  • Human bone marrow stromal cells were extracted from total RNA using Trizol reagent (Life Technologies). The poly(A) mRNA is then isolated from total RNA. After poly(A) m NA was reverse transcribed to form a cDNA, the cDNA fragment was inserted into the vector cloning site by SuperScriptll cloning kit (Life Technologies), and DH5oc bacteria were transformed to form a cDNA plasmid library. The sequence of the 5' end of the randomly selected clone was determined by the dideoxy method. Comparing the determined cDNA sequence with the existing public DNA sequence database revealed that the DNA sequence of one cDNA clone was a new full-length cDNA.
  • the DNA sequence contained in the new clone was bidirectionally determined by synthesizing a series of primers. Computer analysis indicated that the full-length cDNA contained in the clone was a new cDNA sequence (shown as SEQ ID NO: 1) encoding a new protein (as shown in SEQ ID NO: 2). This protein was named human phosphatidylethanolamine binding protein PEBP4, and its coding gene was named human phosphatidylethanolamine binding protein PEBP4 gene.
  • the sequence SEQ ID NO: 1 is 874 bp in length and comprises a 64 bp 5' non-coding region and a 125 bp 3' non-coding region encoding a polypeptide of 227 amino acids.
  • the molecular weight of the unglycosylated mature molecule is theoretically calculated to be about 25 kD. It belongs to the phosphatidylethanolamine binding protein family of molecules.
  • Example 2 Cloning of the coding sequence of human PEBP4 protein by RT-PCR
  • RNA ⁇ cells taken 5 ⁇ 1 ⁇ ⁇ 01 12 and igo-dT - 18 were mixed and reverse transcription.
  • the reverse transcription system was 20 ⁇ l, and after the reaction was completed, 80 ⁇ l dd 3 ⁇ 40 was added for dilution.
  • the primers used for PC amplification of PEBP4 were as follows, with ⁇ -act in as a positive control:
  • Antisense primer 5 - TCTAGCAGGCAGCTATCTCC-3 ' (SEQ ID NO: 4).
  • the PC reaction volume was 50 ⁇ l, which contained the reverse transcription template 10 ⁇ 1, 0.5 mM primer, 0.2 mM dNTP and lU rTaq DNA polymerase (Takara), and the amplification parameters were 95 ° C for 15 seconds, 57 ° C for 30 seconds, At 72 ° C for 30 seconds, after 28 cycles, the PCR product was initially confirmed by 1. 5% agarose gel electrophoresis. The result of DNA sequence analysis revealed that the DNA sequence of the PCR product was identical to that of 64-750 shown in SEQ ID NO: 1.
  • Example 3 Northern blot analysis of human PEBP4
  • Northern blotting was performed as follows: The filter to be tested was placed in 10 ml of a pre-warmed hybridization solution at 68 ° C, pre-hybridized in a hybridization oven (Bellco) at 68 ° C for 30 minutes; the labeled cDNA probe was 95 Denture at 100 °C for 2 to 5 minutes, add rapidly to the ice and add the hybridization solution (final concentration of cDNA probe is 2 ⁇ 10ng/ml or l ⁇ 2 X 10 6 cpm/ml), mix well, at 68° C hybridization for 2 hours.
  • Bellco hybridization oven
  • the filter was rinsed several times with 2xSSC, 0.05% SDS at room temperature, followed by shaking for 30 to 40 minutes, during which the lotion was changed several times. Subsequently, it was washed with 0. lxSSC, 0.1% SDS at 50 ° C for 20 to 40 minutes. Finally, the filter is wrapped in plastic wrap, at -70. C exposed X-ray film for 24 to 48 hours.
  • the reagents used in the PCR reaction are
  • end primer sequence 5, end primer sequence: 5, - GCGAATTCTGGGTTGGACAAT GAGGCTG-3, (SEQ ID NO: 5). 3, end primer sequence: 5 '-TCGAATTC CTAGCAGGCAGCTATC TCC-3' (SEQ ID NO: 6).
  • the obtained PCR product was purified, digested with EcoR I and then recombined with the expression vector plasmid pGEX-2T (Pharmacia) according to a conventional method and transformed into competent E. coli DH5a, and the clone was picked.
  • the positive clone was identified by EcoR I digestion.
  • the positive clone was identified by BamH I digestion, and the product was analyzed by 0.8% agarose gel electrophoresis.
  • the PEBP4 protein was obtained by excision of GST by thrombin (Sigma) and the molecular weight was about 25 kD.
  • the human PEBP4 recombinant protein obtained in Example 4 was used to immunize an animal to produce an antibody, as described below.
  • the recombinant molecules are separated by chromatography and used. Separation can also be carried out by SDS-PAGE gel electrophoresis, and the electrophoresis band is excised from the gel and emulsified with an equal volume of complete Freund's adjuvant.
  • Mice were intraperitoneally injected with 50-100 ⁇ g/0.2 ml of the emulsified protein. After 14 days, mice were intraperitoneally injected with a dose of 50-100 ⁇ g/0.2 ml with the same antigen emulsified with incomplete Freund's adjuvant to boost the immunization.
  • Example 5 The anti-PEBP4 antibody (1:100) obtained in Example 5 was then diluted with the primary antibody dilution in the kit and incubated with the sections for 2 hr at 4 °C. After washing with PBST (PBS containing 0.1% Tween 20), the HRP-conjugated secondary antibody solution was added dropwise, and allowed to stand at room temperature for 30 min. After washing, it was incubated with ABC El ite reagent for 30 min at room temperature, and washed with PBS. Observed under the microscope. Immunohistochemistry results showed that breast cancer tissues highly expressed PEBP4 protein. In the normal breast tissue and breast cancer tissues detected, 6 normal breast tissues did not express PEBP4 protein, but 6 breast cancer tissues highly expressed PEBP4 protein (Fig. 2).
  • Example 7 Construction of human PEBP4 eukaryotic expression vector and eukaryotic gene transfection
  • the primer sequences used in the PC reaction are:
  • the 5' primer sequence is -
  • the PEBP4 eukaryotic expression plasmid DNA was transfected into TNFoc-sensitive rat L929 cells with liposome Lipof ectAMINE reagent (Invitrogen), and the pcDNA3.1 plasmid vector was used as an irrelevant control.
  • Lipof ectAMINE reagent Invitrogen
  • the main steps are as follows: The plasmid DNA to be transfected is mixed with the liposome LipofectAMINE in a certain ratio and allowed to react at room temperature for 45 minutes; 60-80% confluent is grown in MCF-7 cells of 6-well cell culture plate, using 0PTI- After washing twice with MEM serum-free medium (Inv itrogen), the plasmid DNA-liposome mixture was added, cultured at 37 ° C 5% CO 2 for 6-8 hours, and an equal volume of normal medium containing 20% serum was added. Fresh culture medium was replaced after 6 hours of incubation. Transient expression was collected 48 hours after transfection and subjected to Western blot analysis to detect transfection effects.
  • Example 8 Western blot detection
  • L929 cells transiently transfected with expression of PEBP4 protein in Example 7 were treated with 20 ng/ml TNFoc (Shanghai Saida) for 20 hr, and then lysed with cell lysate (Cell Signaling). The supernatant was centrifuged at 4 ° C for 13,000 rpm x lOmin, and protein quantification was performed using a BCA protein assay kit (PIERCE). The protein samples were subjected to SDS-PAGE, followed by transfer to a nitrocellulose membrane (Schleicher & Schuell) at a constant voltage of 100 V at 4 ° C, stained with Ponceau and labeled with size and orientation.
  • TNFoc Cell Signaling
  • Block for 2 hours at room temperature (5% TBST solution of skimmed milk powder), dilute the primary antibody with blocking solution, and incubate for 1 hour at room temperature.
  • TBST (0. 05% Tween 20 in TBS solution) was washed for 15 minutes, 3 times, and the secondary antibody was diluted with blocking solution and incubated for 2 hours at room temperature.
  • the primary antibody used for Western blot detection was the anti-PEBP4 antibody obtained in Example 5.
  • the secondary antibody was HRP-labeled anti-rabbit IgG (Cell Signaling).
  • siRNA 21-nt long PEBP4 interfering RNA (siRNA) oligonucleotide (Prol igo) was synthesized in vitro, and the primer used was - sense strand 5, -GGA AAA GUC AUC UCU CUC CTT (SEQ ID NO: 9)
  • Antisense strand 5 -GGA GAG AGA UGA CUU UUC CTT (SEQ ID NO: 10).
  • Antisense strand 5 -GGA GAG AGU AGA CUU UUC CTT (SEQ ID NO: 12).
  • the annealing procedure for siRNA was as follows: Annealing buffer (100 mM potassium acetate, 30 mM HEPES-K0H, pH 7.4, 2 mM magnesium acetate) and 21-nt NAs (20 ⁇ ) were incubated at 90 ° C for 1 min and then 37 ° C Incubate for 1 hr.
  • siRNA transfection of eukaryotic cells was performed using Oligofectamine reagent (Inv itrogen) to interfere with the expression of PEBP4 protein in human breast cancer cell MCF-7 cells.
  • the main steps are as follows: The siRNA to be transfected is diluted with serum-free 0pt i-MEM (Invitrogen), mixed with Oligofectamine in a certain ratio, and allowed to react at room temperature for 20 minutes; grown in 6-well cell culture plate or 10 mm culture dish to be transferred. The cells were cultured to 60-80% confluence, washed twice with Opt i-MEM serum-free medium, and then added to normal medium in the manner of conventional cultured cells. The RNA-liposome mixture was dropped, cultured at 37 ° C 5% CO 2 for 48 hours, and the cells were collected for T-PC and Western blot analysis.
  • L929 cells overexpressing PEBP4 protein in Example 7, and MCF-7 cells in Example 9 which were down-regulated by RNA interference leading to PEBP4 protein expression were treated with 20 ng/ml TNFoc (Shanghai Saida) for 20 hr, and then treated.
  • the cells were suspended in 50 ⁇ l of the staining solution, and added to ⁇ AnnexinV (ApoAlert Annexin V Apoptosis Detection Kit, Becton Dickinson) for 10 minutes, and then added with 0.5 ⁇ l PI (propidium iodide) for 5 minutes.
  • Flow cytometry (Becton Dickinson) was used to detect apoptosis.
  • Example 12 In vitro screening of PEBP4 inhibitors and agonists
  • Test substance 1 is the anti-PEBP4 antibody prepared in Example 5
  • Test substance 2 is the PEBP4 interfering RNA prepared in Example 9
  • Test substance 3 is the PEBP4-GST fusion protein prepared in Example 4
  • Volume of normal saline is the anti-PEBP4 antibody prepared in Example 5
  • Test substance 2 is the PEBP4 interfering RNA prepared in Example 9
  • Test substance 3 is the PEBP4-GST fusion protein prepared in Example 4
  • Volume of normal saline is the volume of normal saline.
  • Test 1 and Test 2 increased the apoptotic rate of MCF-7 cells and L929 cells compared to the control group, indicating that the two test substances are potential inhibitors of PEBP4 polypeptide;
  • the apoptotic rate of MCF-7 cells and L929 cells was increased, indicating that test substance 3 is an agonist of the potential PEBP4 polypeptide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation de la protéine 4 se liant à la phosphatidyléthanolamine (PEBP4) ou de la séquence de codage de cette protéine en vue de fabriquer des compositions inhibant l'apoptose cellulaire. Le polypeptide de l'invention constitue une nouvelle molécule qui se lie à la phosphatidyléthanolamine, joue un rôle dans la transduction de signal et présente une résistance à l'apoptose cellulaire.
PCT/CN2007/070627 2007-09-05 2007-09-05 Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine WO2009030087A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070627 WO2009030087A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070627 WO2009030087A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine

Publications (1)

Publication Number Publication Date
WO2009030087A1 true WO2009030087A1 (fr) 2009-03-12

Family

ID=40428438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070627 WO2009030087A1 (fr) 2007-09-05 2007-09-05 Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine

Country Status (1)

Country Link
WO (1) WO2009030087A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118516408A (zh) * 2024-06-07 2024-08-20 北京农学院 一种PEBP4基因及其siRNA在制备治疗猪繁殖与呼吸综合征的药物或试剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1477117A (zh) * 2002-08-19 2004-02-25 浙江大学免疫学研究所 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途
CN1948484A (zh) * 2005-10-14 2007-04-18 浙江大学 抑制人hPEBP4基因表达的siRNA及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1477117A (zh) * 2002-08-19 2004-02-25 浙江大学免疫学研究所 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途
CN1948484A (zh) * 2005-10-14 2007-04-18 浙江大学 抑制人hPEBP4基因表达的siRNA及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WANG, XIAOJIAN ET AL.: "Cloning and characterization of novel molecules, hPEBP4 and IPP2, from human bone marrow stromal cells", CHINESE DOCTORAL DISSERTATIONS & MASTER'S THESES FULL-TEXT DATABASE (DOCTOR) MEDICINE AND HEALTH SCIENCES, 2004, pages E072 - 7 *
XIAOJIAN WANG ET AL.: "A Novel Human Phosphatidylethanolamine-binding Protein Resists Tumor Necrosis Factor a-induced Apoptosis by Inhibiting Mitogen-activated Protein Kinase Pathway Activation and Phosphatidylethanolamine Extemalization", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 44, 2004, pages 45855 - 45864, XP055351513 *
XIAOJIAN WANG ET AL.: "Silencing of Human hosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-a-Induced Apoptosis and Cell Growth Arrest", CLIN CANCER RES, vol. 11, no. 20, 2005, pages 7545 - 7553, XP055351518 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118516408A (zh) * 2024-06-07 2024-08-20 北京农学院 一种PEBP4基因及其siRNA在制备治疗猪繁殖与呼吸综合征的药物或试剂中的应用
CN118516408B (zh) * 2024-06-07 2024-12-06 北京农学院 一种PEBP4基因及其siRNA在制备治疗猪繁殖与呼吸综合征的药物或试剂中的应用

Similar Documents

Publication Publication Date Title
CN101300346A (zh) 新型生理物质nesfatin及其相关物质、以及它们的用途
JP2002512521A (ja) ３２個のヒト分泌タンパク質
CN107412727B (zh) 蛋白PACRGL的多肽与热休克蛋白gp96形成的复合物在制备治疗与预防癌症的药物中的应用
JP2002514925A (ja) １９個のヒト分泌タンパク質
JP2001517943A (ja) ヒト膵炎関連タンパク質、ｐａｐ−２
JP2001503628A (ja) 新規なヒスタミンｈ２受容体
JP2001509018A (ja) Ｐ５３応答マウス遺伝子ｅｉ１２４に類似なｄｎａがコードするヒトアポトーシス関連タンパク質
CN110237257B (zh) Ube3a泛素化PP2A激活因子PTPA在治疗天使综合症和孤独症中的应用
WO2010087497A1 (fr) Composition pharmaceutique et préparation pharmaceutique pour traitement de tumeurs
CN106913863B (zh) NUP188蛋白的多肽与热休克蛋白gp96的复合物在制备治疗与预防癌症药物中的应用
CN106913862B (zh) 蛋白TIF1-β的多肽与热休克蛋白gp96形成的复合物在制备治疗与预防癌症的药物中的应用
JP2001511645A (ja) ヒトＣ５ａ様受容体
WO2009030087A1 (fr) Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine
WO2021228052A1 (fr) Inhibiteur du complément macromoléculaire biologique spécifique à une cible, son procédé de préparation et son utilisation
JPH1156376A (ja) ヒトＩκＢ−β
CN106822869B (zh) DEF8蛋白的多肽与热休克蛋白gp96的复合物在制备治疗与预防癌症药物中的应用
AU2003231196C1 (en) Androgen-regulated PMEPA1 and cancer
JP2001509015A (ja) ヒト塩素イオンチャネルタンパク質（ｈｃｃｐ）
WO2001060855A1 (fr) Nouvelle proteine humaine associee a la regulation du cycle cellulaire et sa sequence de codage
JP2001517945A (ja) ヒト腫瘍形成関連タンパク質、ｈｔａｐ
CN100425695C (zh) 新型人Rab GTP酶，其编码序列及用途
CN100381466C (zh) 一种人Pif1基因、其编码蛋白及其应用
WO2009030094A1 (fr) Fonction et utilisation d'une nouvelle protéine induisant une apoptose associée aux lysosomes contenant les domaines ph et fyve (lapf)
CN100415299C (zh) 胚泡着床相关因子及其用途
CN117586972A (zh) 肺癌相关多肽、复合物、药物组合物及用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801036

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801036

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载